Use of carefully titrated ultra ‐low doses of alteplase in infected haemothorax caused by initial alteplase use to drain loculated malignant pleural effusion
This case highlights the safe use of very low doses of alteplase ranging from 0.25 to 0.5 mg following pleural bleeding after the use of alteplase to treat a patient with symptomatic malignant loculated effusion and may demonstrate there may be a use for carefully titrated alteplase in the pleural space after pleural bleeding has stopped to treat pleural infection. AbstractAlteplase as a fibrinolytic can be used to break up fibrin to encourage clot breakdown for clinical use. In the pleural space, it is used for symptomatic loculated malignant pleural effusions and pleural infections and can potentially avoid the need f...
Source: Respirology Case Reports - August 10, 2023 Category: Respiratory Medicine Authors: Jeong Suk Oh,
Chris Yoo,
Donny Wong Tags: CASE REPORT Source Type: research
Comparing adverse Events of tenecteplase and alteplase: A Real-World analysis of the FDA adverse Event Reporting System (FAERS)
CONCLUSION: This study identified and compared signals of ADRs associated with tenecteplase and alteplase, although tenecteplase is as effective as alteplase and has advantages such as ease of use and affordability, it cannot replace alteplase in the treatment of AIS until its safety profile is fully recognized. Additionally, previously unreported ocular ADRs and pneumonia were identified, providing valuable insights into the relationship between ADRs and the use of these thrombolytic drugs. These findings underscore the importance of continuous monitoring and effective detection of AEs to ultimately enhance the safety of ...
Source: Expert Opinion on Drug Safety - August 9, 2023 Category: Drugs & Pharmacology Authors: Fang-E Shi Zhe Yu Chengyue Sun Peiliang Gao Haiyan Zhang Jihong Zhu Source Type: research
Tenecteplase vs. Alteplase for Intravenous Thrombolytic Therapy of Acute Ischemic Stroke: A Systematic Review and Meta-Analysis
ConclusionsThis meta-analysis showed that tenecteplase was not inferior to alteplase in early thrombolytic therapy in patients with AIS, and was even better than alteplase on some efficacy outcomes with no significant differences in safety. However, as a result of some inherent limitations of this study, more high-quality prospective clinical studies are needed to confirm these results. (Source: Neurology and Therapy)
Source: Neurology and Therapy - August 8, 2023 Category: Neurology Source Type: research
Low-dose intravenous recombinant tissue plasminogen activator in acute ischemic stroke without large vessel occlusion screened by 3T MRI
CONCLUSIONS: Our study indicates the efficacy and safety of low-dose rTPA treatment for AIS without LVO within 4.5 hours. Patient selection for rTPA by 3T MRI decreased complications and mortality.PMID:37522667 | DOI:10.26355/eurrev_202307_33126 (Source: Pharmacological Reviews)
Source: Pharmacological Reviews - July 31, 2023 Category: Drugs & Pharmacology Authors: Q-S Huynh C-C Tran H-T Nguyen-Thi T-T Nguyen H-L Phan-Thi D-T Luu-Dang M-T Le M-D Nguyen Source Type: research
Low-dose intravenous recombinant tissue plasminogen activator in acute ischemic stroke without large vessel occlusion screened by 3T MRI
CONCLUSIONS: Our study indicates the efficacy and safety of low-dose rTPA treatment for AIS without LVO within 4.5 hours. Patient selection for rTPA by 3T MRI decreased complications and mortality.PMID:37522667 | DOI:10.26355/eurrev_202307_33126 (Source: European Review for Medical and Pharmacological Sciences)
Source: European Review for Medical and Pharmacological Sciences - July 31, 2023 Category: Drugs & Pharmacology Authors: Q-S Huynh C-C Tran H-T Nguyen-Thi T-T Nguyen H-L Phan-Thi D-T Luu-Dang M-T Le M-D Nguyen Source Type: research
